Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
/ adverse effects
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
Cross-Sectional Studies
Female
Follow-Up Studies
Humans
Immunotherapy
/ adverse effects
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Muscle, Skeletal
/ drug effects
Nivolumab
/ adverse effects
Prognosis
Retrospective Studies
Sarcopenia
/ chemically induced
Survival Rate
Tomography, X-Ray Computed
Immunotherapy
NSCLC
nivolumab
sarcopenia
skeletal muscle
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
21
11
2018
revised:
11
12
2018
accepted:
12
12
2018
pubmed:
3
1
2019
medline:
8
2
2020
entrez:
3
1
2019
Statut:
ppublish
Résumé
Sarcopenia represents one of the hallmarks of all chronic disease, including non-small cell lung cancer (NSCLC). A computed tomography scan is an easy modality to estimate the skeletal muscle mass through cross-sectional image analysis at the level of the third lumbar vertebra (L3). Baseline skeletal muscle mass (SMM) was evaluated using gender-specific cutoffs for skeletal muscle index in NSCLC patients administered immunotherapy with nivolumab to evaluate its possible correlations with clinical outcomes. From April 2015 to August 2018, 23 stage IV NSCLC patients were eligible for image analysis. Nine patients (39.1%) had low SMM. Among patients with baseline low and non-low SMM, median progression free survival was 3.1 and 3.8 months, respectively (P = 0.0560), while median overall survival was 4.1 and 13 months, respectively (P = 0.2866). This hypothesis-generating preliminary report offers the opportunity to speculate about the negative influence of sarcopenia on immune response. In our opinion, nutritional status could affect the clinical outcomes of immunotherapy, even if we cannot make definitive conclusions here. Further studies on the topic are required.
Identifiants
pubmed: 30600905
doi: 10.1111/1759-7714.12965
pmc: PMC6360197
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
347-351Informations de copyright
© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Br J Cancer. 2017 Jan;116(3):310-317
pubmed: 28072766
Invest New Drugs. 2017 Aug;35(4):436-441
pubmed: 28396974
J Thorac Oncol. 2018 Jul;13(7):895-903
pubmed: 29751134
Proc Nutr Soc. 2015 Nov;74(4):348-54
pubmed: 25809872
Oncotarget. 2015 Dec 29;6(42):44123-33
pubmed: 26675759
Eur J Cancer. 2016 Sep;65:33-42
pubmed: 27451022
Front Immunol. 2017 Mar 13;8:277
pubmed: 28348567
J Allergy Clin Immunol. 2017 Jan;139(1):335-346.e3
pubmed: 27372564
J Anim Sci. 2008 Apr;86(14 Suppl):E75-83
pubmed: 17709786
Oncologist. 2018 Nov;23(11):1358-1365
pubmed: 29934411
Aging (Albany NY). 2012 Aug;4(8):535-46
pubmed: 22935594
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Ann Oncol. 2017 Sep 1;28(9):2107-2118
pubmed: 28911059
Autoimmun Rev. 2018 May;17(5):518-529
pubmed: 29526638
Thorac Cancer. 2018 Dec;9(12):1623-1630
pubmed: 30259689